Focus Partners Wealth Boosts Eli Lilly Holdings to $124.30 Million

Investment firm increases stake in pharmaceutical giant by 8.2% in Q3 2025

Mar. 16, 2026 at 10:05am

Got story updates? Submit your updates here. ›

Focus Partners Wealth, an investment management firm, increased its position in Eli Lilly and Company (NYSE: LLY) by 8.2% during the third quarter of 2025, according to a recent SEC filing. The firm now owns 163,922 shares of the pharmaceutical company's stock, valued at $124,296,000.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for its innovative drugs and therapies. The increase in Focus Partners Wealth's stake suggests the firm sees long-term growth potential in Lilly's business and product pipeline.

The details

Focus Partners Wealth acquired an additional 12,394 shares of Eli Lilly during the third quarter, bringing its total holdings to 163,922 shares. This represents an 8.2% increase in the firm's position compared to the previous quarter. Eli Lilly is one of Focus Partners Wealth's top holdings, accounting for a significant portion of the firm's $1.5 billion in assets under management.

  • Focus Partners Wealth filed the 13F report disclosing the increased Eli Lilly holdings on March 16, 2026.
  • The firm acquired the additional Eli Lilly shares during the third quarter of 2025.

The players

Focus Partners Wealth

An investment management firm based in New York City that oversees approximately $1.5 billion in assets.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana that develops and markets a wide range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

The increase in Focus Partners Wealth's Eli Lilly holdings suggests the firm sees continued growth potential in the pharmaceutical company's business, which could be driven by new drug approvals, pipeline advancements, and strong demand for its existing portfolio of medicines.